PDCD1 and cancer: This approach represents an innovative and ingenious combination therapy.[110] The results of a clinical study of anti‐TIGIT combined with anti‐PD‐1 in the treatment of non‐small‐cell lung cancer are encouraging, indicating the potential of TIGIT for cancer therapy.